A pharmaceutical company was fined over 30 million!

In recent years, in order to strengthen drug quality supervision and ensure the safety of drug use by the public, the country and even localities have continuously introduced relevant documents and measures to supervise drug quality and safety
.
Under the continuous tightening of supervision, it is not uncommon for pharmaceutical companies to be punished and warned by the provincial drug regulatory bureaus for the production and sales of counterfeit and inferior drugs
.
This year, a large number of companies have been fined for producing and selling substandard drugs
.
Judging from the punishment announcements in various places, the results of the punishment of pharmaceutical companies mainly include the order to make corrections, warnings, the prohibition of relevant legal representatives from engaging in drug production and business activities, and the imposition of fines
.
Among them, it is worth noting that many are huge fines
.
For example, recently, Guizhou Bailing Group issued an announcement that its subsidiary He Rentang Pharmaceutical was fined RMB 32,068,379.
63 by the Guiyang Market Supervision Bureau for “not strictly implementing the registered process to produce” Kangfuling Capsules, and confiscated drugs that were illegally produced and recalled after sales.
” "Kang Fu Ling Capsules" 238,922 boxes
.
The announcement showed that when Herentang Pharmaceutical produced the drug "Kangfuling Capsules", it illegally extracted and added cork extract powder to ensure that the product content meets the standard requirements
.
Failure to organize production in strict accordance with the registration process is in violation of the provisions of Article 10, Paragraph 1 and Article 49, Paragraph 1 of the "Drug Administration Law" (2015 revised edition)
.
According to regulations, the Guiyang City Market Supervision Administration ordered Herentang Pharmaceutical to immediately stop the illegal activities and impose administrative penalties
.
However, because Herentang Pharmaceuticals violated the law for the first time and voluntarily recalled the batch of products involved, and has not received new adverse reaction reports of the batches involved, Guiyang City Market Supervision Administration gave it a reduced administrative penalty: confiscation 238,922 boxes of "Kangfuling Capsules" were recalled after illegal production and sales; the illegal income totaling 32,068,379.
63 yuan was confiscated
.
In fact, pharmaceutical companies are fined in the industry for selling inferior drugs and counterfeit drugs
.
On November 19, Guangxi Jinhaitang Pharmaceutical Co.
, Ltd.
received a warning and punishment for suspected illegal addition of purchased bitter almond water during the production of Chuanbei Qingfei syrup.

.
On the same day, the Anhui Provincial Food and Drug Administration released information on administrative penalties.
Among them, a pharmaceutical company was fined RMB 1,701,335 for suspected production and sales of inferior drugs
.
In addition, within a few months, the Food and Drug Administration in Tianjin, Shandong Province, Fujian Province and many other places have also issued information disclosure forms for administrative punishment cases, involving many pharmaceutical companies who have been fined for violations and fines of various sizes
.
Among them, it is worth noting that the penalty amount, especially the penalty amount for selling inferior drugs as a whole, is becoming higher and higher
.
Analysis believes that, in fact, pharmaceutical companies are often fined in the industry for non-compliant behaviors such as selling inferior drugs
.
From the point of view of the penalty amount, especially the penalty amount for selling inferior drugs, it is becoming higher and higher, mainly because in accordance with the new version of the "Drug Administration Law", the lower limit of selling counterfeit drugs is aimed at selling counterfeit and inferior drugs.
The fine has reached 1.
5 million, and the minimum fine for retail substandard drugs has also reached 100,000
.
In this context, the industry generally believes that with the continuous tightening of industry supervision, the cost of violations will greatly increase
.
According to the industry, if pharmaceutical companies continue to touch the "red line", cases of huge fines will emerge in the future
.
Therefore, in the context of increasing industry supervision and increasing frequency of supervision, all pharmaceutical companies need to further strengthen self-discipline and strictly follow the requirements of the new version of the pharmacopoeia to do a good job in every link of planting, production, processing, and circulation.
, To promote the improvement of the overall quality of the pharmaceutical industry
.
In addition, relevant companies also need to accelerate the standardization of drug production to further ensure drug quality and safety
.
In short, only by standardizing operations and strictly controlling quality can an enterprise go further
.